Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

April CHMP Meeting: Disappointment In Advance For AB Science, Gilead Hopeful On Biktarvy

Executive Summary

You may also be interested in...



Ambitious AB Science Gets Masitinib Win For Severe Asthma

Plagued by concerns on the integrity of data and compliance issues with its clinical practices, the French firm still believes masitinib could be effective for ALS, multiple sclerosis, cancers, asthma and even Alzheimer's.

France Lifts Clinical Hold From AB Science’s Masitinib

After two years on clinical hold, the French biotech has resolved quality and pharmacovigilance problems that forced it to suspend studies of masitinib, moving it a step closer to restarting trials in its home country.

EMA Decides Fast-Track Fate Of Masitinib And Anthrax Antitoxin

The European Medicines Agency is this week deciding whether it will fast track its review of orphan drugs from two companies, one of which has previously tried but failed to get the same product approved for sale in the EU.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel